Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is an FDA supplemental approval action for doxycycline hyclate labeling; it documents a regulatory decision, not clinical trial evidence or efficacy data.